Prometheus Biosciences, Inc.
(NASDAQ GS: RXDX)
Rigrodsky Law, P.A. is investigating Prometheus Biosciences, Inc. (“Prometheus”) regarding possible breaches of fiduciary duties and other violations of law related to Prometheus’ agreement to be acquired by Merck & Co., Inc. Under the terms of the agreement, Prometheus shareholders will receive $200.00 per share in cash.